Concentra will acquire the firm for $.36 per share in cash in a deal that was approved by Elevation Oncology's board.

The drug is already approved in the EU for transthyretin amyloidosis with polyneuropathy but now covers patients with cardiomyopathy.

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

Due to financial, logistical, and regulatory barriers, only two in 10 patients eligible for CAR T-cell therapy in the US ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...